sucnr1

NF-56-EJ40 is an effective and highly selective antagonist of human SUCNR1 with an IC50 of 25 nM and a Ki of 33 nM.

SUCNR1-IN-2 (Statement 35) is an effective SUCNR1 inhibitor for studying neurodegenerative diseases.

SUCNR1-IN-1 (Compound 20) is a potent SUCNR1 inhibitor with an IC50 of 88 nM against hSUCNR1, used in research on rheumatoid arthritis, liver fibrosis, and obesity [1].

Succinate/succinate receptor antagonist 1 is a potent succinate receptor antagonist. Succinate/succinate receptor antagonist 1 interrupts succinate signals in gingival tissue and inhibits the activation of SucnRl Antagonist 1. Its IC50 value is 20 μsouth of the coast. Succinate/succinate receptor antagonist 1 can be used to treat periodontal disease.

cis-Epoxysuccinic acid is a potential agonist of Succinate receptor 1 and inhibitor of Isocitrate lyase 1 for use in biochemical experiments.

hGPR91 antagonist 1 is a potent and selective hGPR91 antagonist (IC50: 7 nM).

hGPR91 antagonist 3 is an orally active, potent, and selective hGPR91 antagonist. hGPR91 antagonist 3 is used to study hypertension, autoimmune diseases, and retinal angiogenesis. hGPR91 antagonist 3 has been shown to be effective in the treatment of hypertension, autoimmune disease, and retinal angiogenesis.

NF-56-EJ40 hydrochloride is a potent, high-affinity, and highly selective human SUCNR1 (GPR91) antagonist with an IC50 of 25 nM and a Ki of 33 nM, and shows almost no activity towards rat SUCNR1. NF-56-EJ40 hydrochloride has high affinity for humanized rat SUCNR1 with a Ki value of 17.4 nM.